Our clinical experience with zonisamide in resistant generalized epilepsy syndromes.

A. Kelemen, György Rásonyl, Magdolna Neuwirth, Gábor Barcs, A. Szűcs, R. Jakus, Dániel Fabó, Vera Juhos, Beatrix Pálfy, P. Halász

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Zonisamide is licensed in the European Union for adjunctive therapy for partial epilepsy, but its efficacy in generalized epilepsy was less explored. This prospective observational study included 47 patients (mean age 29 years, range 3-50) with different resistant generalized epilepsy syndromes: idiopathic generalized syndromes (IGE) 15 patients, (juvenile myoclonic epilepsy four, absence epilepsy four, myoclonic absence two, unclassified IGE five), progressive myoclonic epilepsy type 1 (PME1) four, severe myoclonic epilepsy of infancy (SMEI) three, borderline SMEI three, Lennox-Gastaut syndrome/secondary generalized epileptic encephalopties 23 patients. All patients were followed up for at least six months. The mean dose given was 367 mg/day (range 100-600 mg/day), the patients received at least one and no more than two concomitant AE. Response was defined as more than 50% seizure reduction or seizure freedom. The best effect was achieved in PME one, all the patients were responders. Myoclonic seizures were reduced 80%, none of the patients had generalized tonic clonic (GTC) seizures. In two of the four patients all other antiepileptics were tapered of (including piracetam), so they were GTC seizure and almost myoclonia free on zonisamide only. Responder rates were in GEFS +/- SME 62.5%, in resistant IGE 62.5%, and in epileptic encephalopathies 33.3% patients. Tolerance after initial efficacy developed in six patients. Adverse effects were mild: weight loss, somnolence and confusion were repeatedly reported. Three patients reported cognitive improvement. Clinical benefit of a broad spectrum antiepileptic zonisamide extends across seizure types, ages and epilepsy syndromes. The efficacy in PME proved to be excellent.

Original languageEnglish
Pages (from-to)187-192
Number of pages6
JournalIdeggyógyászati szemle
Volume64
Issue number5-6
Publication statusPublished - Mar 30 2011

Fingerprint

zonisamide
Generalized Epilepsy
Myoclonic Epilepsy
Seizures
Anticonvulsants
Unverricht-Lundborg Syndrome
Juvenile Myoclonic Epilepsy
Piracetam

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Our clinical experience with zonisamide in resistant generalized epilepsy syndromes. / Kelemen, A.; Rásonyl, György; Neuwirth, Magdolna; Barcs, Gábor; Szűcs, A.; Jakus, R.; Fabó, Dániel; Juhos, Vera; Pálfy, Beatrix; Halász, P.

In: Ideggyógyászati szemle, Vol. 64, No. 5-6, 30.03.2011, p. 187-192.

Research output: Contribution to journalArticle

Kelemen, A, Rásonyl, G, Neuwirth, M, Barcs, G, Szűcs, A, Jakus, R, Fabó, D, Juhos, V, Pálfy, B & Halász, P 2011, 'Our clinical experience with zonisamide in resistant generalized epilepsy syndromes.', Ideggyógyászati szemle, vol. 64, no. 5-6, pp. 187-192.
Kelemen, A. ; Rásonyl, György ; Neuwirth, Magdolna ; Barcs, Gábor ; Szűcs, A. ; Jakus, R. ; Fabó, Dániel ; Juhos, Vera ; Pálfy, Beatrix ; Halász, P. / Our clinical experience with zonisamide in resistant generalized epilepsy syndromes. In: Ideggyógyászati szemle. 2011 ; Vol. 64, No. 5-6. pp. 187-192.
@article{aca5376e0cf848bfac2247eafcca7e6b,
title = "Our clinical experience with zonisamide in resistant generalized epilepsy syndromes.",
abstract = "Zonisamide is licensed in the European Union for adjunctive therapy for partial epilepsy, but its efficacy in generalized epilepsy was less explored. This prospective observational study included 47 patients (mean age 29 years, range 3-50) with different resistant generalized epilepsy syndromes: idiopathic generalized syndromes (IGE) 15 patients, (juvenile myoclonic epilepsy four, absence epilepsy four, myoclonic absence two, unclassified IGE five), progressive myoclonic epilepsy type 1 (PME1) four, severe myoclonic epilepsy of infancy (SMEI) three, borderline SMEI three, Lennox-Gastaut syndrome/secondary generalized epileptic encephalopties 23 patients. All patients were followed up for at least six months. The mean dose given was 367 mg/day (range 100-600 mg/day), the patients received at least one and no more than two concomitant AE. Response was defined as more than 50{\%} seizure reduction or seizure freedom. The best effect was achieved in PME one, all the patients were responders. Myoclonic seizures were reduced 80{\%}, none of the patients had generalized tonic clonic (GTC) seizures. In two of the four patients all other antiepileptics were tapered of (including piracetam), so they were GTC seizure and almost myoclonia free on zonisamide only. Responder rates were in GEFS +/- SME 62.5{\%}, in resistant IGE 62.5{\%}, and in epileptic encephalopathies 33.3{\%} patients. Tolerance after initial efficacy developed in six patients. Adverse effects were mild: weight loss, somnolence and confusion were repeatedly reported. Three patients reported cognitive improvement. Clinical benefit of a broad spectrum antiepileptic zonisamide extends across seizure types, ages and epilepsy syndromes. The efficacy in PME proved to be excellent.",
author = "A. Kelemen and Gy{\"o}rgy R{\'a}sonyl and Magdolna Neuwirth and G{\'a}bor Barcs and A. Szűcs and R. Jakus and D{\'a}niel Fab{\'o} and Vera Juhos and Beatrix P{\'a}lfy and P. Hal{\'a}sz",
year = "2011",
month = "3",
day = "30",
language = "English",
volume = "64",
pages = "187--192",
journal = "Ideggyogyaszati Szemle",
issn = "0019-1442",
publisher = "Ifjusagi Lap-es Konyvkiado Vallalat",
number = "5-6",

}

TY - JOUR

T1 - Our clinical experience with zonisamide in resistant generalized epilepsy syndromes.

AU - Kelemen, A.

AU - Rásonyl, György

AU - Neuwirth, Magdolna

AU - Barcs, Gábor

AU - Szűcs, A.

AU - Jakus, R.

AU - Fabó, Dániel

AU - Juhos, Vera

AU - Pálfy, Beatrix

AU - Halász, P.

PY - 2011/3/30

Y1 - 2011/3/30

N2 - Zonisamide is licensed in the European Union for adjunctive therapy for partial epilepsy, but its efficacy in generalized epilepsy was less explored. This prospective observational study included 47 patients (mean age 29 years, range 3-50) with different resistant generalized epilepsy syndromes: idiopathic generalized syndromes (IGE) 15 patients, (juvenile myoclonic epilepsy four, absence epilepsy four, myoclonic absence two, unclassified IGE five), progressive myoclonic epilepsy type 1 (PME1) four, severe myoclonic epilepsy of infancy (SMEI) three, borderline SMEI three, Lennox-Gastaut syndrome/secondary generalized epileptic encephalopties 23 patients. All patients were followed up for at least six months. The mean dose given was 367 mg/day (range 100-600 mg/day), the patients received at least one and no more than two concomitant AE. Response was defined as more than 50% seizure reduction or seizure freedom. The best effect was achieved in PME one, all the patients were responders. Myoclonic seizures were reduced 80%, none of the patients had generalized tonic clonic (GTC) seizures. In two of the four patients all other antiepileptics were tapered of (including piracetam), so they were GTC seizure and almost myoclonia free on zonisamide only. Responder rates were in GEFS +/- SME 62.5%, in resistant IGE 62.5%, and in epileptic encephalopathies 33.3% patients. Tolerance after initial efficacy developed in six patients. Adverse effects were mild: weight loss, somnolence and confusion were repeatedly reported. Three patients reported cognitive improvement. Clinical benefit of a broad spectrum antiepileptic zonisamide extends across seizure types, ages and epilepsy syndromes. The efficacy in PME proved to be excellent.

AB - Zonisamide is licensed in the European Union for adjunctive therapy for partial epilepsy, but its efficacy in generalized epilepsy was less explored. This prospective observational study included 47 patients (mean age 29 years, range 3-50) with different resistant generalized epilepsy syndromes: idiopathic generalized syndromes (IGE) 15 patients, (juvenile myoclonic epilepsy four, absence epilepsy four, myoclonic absence two, unclassified IGE five), progressive myoclonic epilepsy type 1 (PME1) four, severe myoclonic epilepsy of infancy (SMEI) three, borderline SMEI three, Lennox-Gastaut syndrome/secondary generalized epileptic encephalopties 23 patients. All patients were followed up for at least six months. The mean dose given was 367 mg/day (range 100-600 mg/day), the patients received at least one and no more than two concomitant AE. Response was defined as more than 50% seizure reduction or seizure freedom. The best effect was achieved in PME one, all the patients were responders. Myoclonic seizures were reduced 80%, none of the patients had generalized tonic clonic (GTC) seizures. In two of the four patients all other antiepileptics were tapered of (including piracetam), so they were GTC seizure and almost myoclonia free on zonisamide only. Responder rates were in GEFS +/- SME 62.5%, in resistant IGE 62.5%, and in epileptic encephalopathies 33.3% patients. Tolerance after initial efficacy developed in six patients. Adverse effects were mild: weight loss, somnolence and confusion were repeatedly reported. Three patients reported cognitive improvement. Clinical benefit of a broad spectrum antiepileptic zonisamide extends across seizure types, ages and epilepsy syndromes. The efficacy in PME proved to be excellent.

UR - http://www.scopus.com/inward/record.url?scp=84855542993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855542993&partnerID=8YFLogxK

M3 - Article

C2 - 21688720

AN - SCOPUS:84855542993

VL - 64

SP - 187

EP - 192

JO - Ideggyogyaszati Szemle

JF - Ideggyogyaszati Szemle

SN - 0019-1442

IS - 5-6

ER -